Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.69 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.69 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081006 | 1.00 | SLC29A1 (0.70) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL6903709 | 1.00 | SLC29A1 (0.70) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL9142042 | 1.00 | SLC29A1 (0.70) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL6887353 | 1.00 | SLC29A1 (0.70) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL2589566 | 0.90 | SLC29A1 (0.58) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL8970336 | 0.90 | SLC29A1 (0.58) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL12552334 | 0.90 | SLC29A1 (0.58) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL8970347 | 0.90 | SLC29A1 (0.58) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL9141461 | 0.89 | SLC29A1 (0.72) | SLC29A1ADORA1ADORA2AADORA2BDPP4 | |
| SCHEMBL13265481 | 0.88 | SLC29A1 (0.67) | SLC29A1ADORA1ADORA2AADORA2BDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116916936-A | Compositions and methods for delivering RNA | 再生技术有限责任公司 | 2023-10-20 | — | — | CN | claimed |
| CN-101346474-A | Selectable nucleotides for improved targeted nucleotide exchange | KEYGENE NV (NL) | 2009-01-14 | — | — | CN | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | claimed |
| CN-1466591-A | Nucleoside derivatives | - | 2004-01-07 | — | — | CN | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | claimed |
| US-6355472-B2 | ACID PHOSPHATASE | AJINOMOTO CO., INC. (JP) | 2002-03-12 | — | — | US | claimed |
| US-20020004590-A1 | Method for producing nucleoside-5'-phosphate ester | MIHARA YASUHIRO (JP) | 2002-01-10 | — | — | US | claimed |
| US-6207435-B1 | MUTANT ACID PHOSPHATASE HAVING DECREASED MICHAELIS CONSTANT FOR A NUCLEOSIDE AND/OR INCREASED TEMPERATURE STABILITY; FOR EFFICIENT PHOSPHORYLATION OF NUCLEOSIDES TO PRODUCE NUCLEOTIDES | AJINOMOTO CO., INC. (JP) | 2001-03-27 | — | — | US | claimed |
| US-6015697-A | ECONOMICAL AND EFFICIENT PROCESS BY REACTING A NUCLEOSIDE WITH A PHOSPHATE DONOR GROUP IN PRESENCE OF MUTANT ACID PHOSPHATASE WITH DECREASED MICHAELIS CONSTANT FOR NUCLEOSIDE OR INCREASED TEMPERATURE STABILITY | AJINOMOTO CO., INC. (JP) | 2000-01-18 | — | — | US | claimed |
| US-5474929-A | Adenosine deaminase gene | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1995-12-12 | — | — | US | claimed |
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12435088-B2 | Salicyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4615517-A1 | CIRCULAR RNA COMPOSITIONS | Orna Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-0755255-A1 | TREATMENT OF TOXOPLASMOSIS | UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996018398-A1 | TREATMENT OF TOXOPLASMOSIS | THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5474929-A | Adenosine deaminase gene | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1995-12-12 | — | — | US | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | SLC29A1 18/4885ADORA1 197/4885ADORA2A 70/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | SLC29A1 18/4885ADORA1 197/4885ADORA2A 70/4885 |
| US-12435088-B2 | Salicyl-adenosinemonosulfamate analogs and uses thereof | ADSL, SLC35B2, ADORA1 | SLC29A1 26/4885ADORA1 3/4885ADORA2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.